HOME >> MEDICINE >> NEWS
Researchers say criterion for diagnosing child abuse based on faulty evidence

WINSTON-SALEM, N.C. At least one of the "definitive" criteria used to diagnose child abuse may be wrong, report researchers from Wake Forest University Baptist Medical Center in the current issue of the British Medical Journal.

"If you read the medical literature, certain eye findings have been considered diagnostic for shaken baby syndrome," says Patrick E. Lantz, M.D., a forensic pathologist at Wake Forest University Baptist Medical Center. "This isn't supported by objective scientific evidence and could result in innocent caregivers going to jail."

Lantz and colleagues researched published reports about perimacular retinal folds, which is a buckling of the retina, the light-sensitive membrane that lines the back of the eye. The injury has been reported in shaken baby syndrome, caused by vigorous shaking of an infant or young child. The shaking may cause bleeding around the brain and in the eyes, resulting in blindness, and can also result in brain damage leading to death.

"Statements in the medical literature indicate that perimacular retinal folds result from the movement of the gel within the eye when an infant or young child is shaken, and that they have no other cause in young children with head injuries," said Lantz. "But our literature review showed that this conclusion is not based on scientifically valid comparative or experimental studies." Lantz and colleagues researched the issue after being involved in the case of a 14-month-old-child who died with perimacular retinal folds and other injuries. The child's father reported that a television set had toppled over, landing on the child's head. However, because of the diagnosis of perimacular retinal folds and hemorrhages, Child Protective Services suspected child abuse and removed a sibling from the home.

"Our investigation found no indication of child abuse other than the eye findings," said Lantz.

A review of the current medical literature showed that the condi
'"/>


25-Mar-2004


Page: 1 2

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
(Date:11/27/2014)... November 27, 2014 Now that Thanksgiving ... has officially launched, Emassagechair.com has announced its ... Discount Event. , Negotiating on behalf of their ... massage chair brands, Emassagechair.com has generated significant buzz in ... and biggest discounts yet. , Shoppers are excited for ...
(Date:11/27/2014)... OXNARD, CA (PRWEB) November 27, 2014 ... All-on-4™ dental implants procedure will help one person ... rehabilitation. , Dr. Saj Jivraj and Dr. Mamaly Reshad ... Woodland Hills, Calif., have launched a website devoted to ... A section of the website would be devoted to ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “Wekho” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review ... follow locations instead of people. , An interesting new way ... for iOS and Android devices. It’s called Wekho and ...
(Date:11/27/2014)... Developers and plugin specialist of Final Cut Pro ... FCPX to the next level. , “ProPip allows users to ... of a mouse,” said Christina Austin, CEO of Pixel Film ... appreciate.” , With ProPip users can show off their ... ProPip is great for commentaries, news casting, and more. PROPIP™ ...
(Date:11/27/2014)... November 27, 2014 This is ... Global Insulin industry. For an overview analysis, the ... application, industry chain structure, industry overview, policy analysis, ... Insulin industry covers information on policy, plans ... cost structure and much more. , ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3
(Date:11/26/2014)... Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ASX: ... delivery systems, today announced that its Chairman and CEO, ... the Piper Jaffray 26th Annual Healthcare Conference at the ... Tuesday, December 2, 2014. The conference ... "live" listen only Webcast. To listen, please go to: ...
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Jaffray Healthcare Conference in New York ... PDT . Dr. Helen Torley , President and ... The presentation will be webcast through the "Investors" section of ... will be made available for 90 days following the event. ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
Cached News: